Excellence in Social and Behavioral Science Group Award
Social and behavioral science is used to enhance the use of information that FDA provides to the public. It includes the development of messages; testing how the public understands information; ensuring that the way FDA delivers information to relevant populations is optimal; and assessing the impact of the information on public understanding, attitudes, and behaviors.
FDA achieves this by conducting social and behavioral research, encouraging extramural research, and seeking expert advice.
2021
Tobacco Products: Principles for Designing and Conducting Tobacco Product Perception and Intention Studies. -- Draft Guidance (CTP)
For providing the first ever FDA draft guidance to tobacco industry on Social and Behavioral Science studies, which is critical to make informed regulatory decisions.
Erin O'Brien, PhD
Alexander Persoskie, PhD
Amber Koblitz, MPH, PhD
Sarah Johnson, PhD
Samantha LohCollado, MPH, JD
Paul Hart, JD
2020
Universal Leukocyte Reduction Cost-Benefit Assessment Team
For outstanding cost-benefit analysis of requiring universal leukocyte reduction for blood donations to improve blood safety.
Richard Forshee, PhD
Hong Yang, PhD
Barbee Whitaker, PhD
Hussein Ezzeldin, PhD
Emily Storch, MD
Anne Eder, MD, PhD
Thomas Henry, PhD
Kinnera Chada, PhD
Mikhail Menis, PhD
Graca Dores, MD, MPH
2019
Naloxone Label Comprehension Study Team
For creating and optimizing a Drug Facts Label to jumpstart a prescription to nonprescription switch for naloxone, a life-saving drug in opioid overdose settings.
Karen Mahoney, MD
Elande Baro, PhD
Rima Izem, PhD
Barbara Cohen
2018
Social Science Modified Risk Tobacco Product (MRTP) Research Team
Excellence in Social and Behavioral Science for modified risk tobacco product research to study consumer perceptions of risk/harm behavioral intentions, and tobacco product use
Cindy Tworek, PhD, MPH
Sarah Johnson, PhD
Alexander Persoskie, PhD
Erin O’Brien, PhD
Amber Koblitz, PhD, MPH
Wendy Slavit, MPH
Aura Lee Morse, MPH
2017
The Office of Prescription Drug Promotion Research Team
For outstanding social science research work on prescription drug promotion that has improved the communication of information about medical drug products to consumers and health care providers
Kathryn J. Aikin, PhD
Helen W. Sullivan, PhD, MPH
Kevin R. Betts, PhD
Amie C. O’Donoghue, PhD
2016
Population Assessment of Tobacco and Health (PATH) Study Management Team
For outstanding scientific contributions in tobacco regulatory science through design and launch of the Population Assessment of Tobacco and Health (PATH) Study
Bridget K. Ambrose, M.P.H., Ph.D.
Nicolette Borek, PhD
Nikolas Pharris-Ciurej, MA, PhD
LCDR Jonathan Kwan, MS (C)
Greta K. Tessman, MA
Cindy Tworek, M.S., M.P.H., Ph.D.
Dana Van Bemmel, M.P.H., Ph.D.
Ling Yang, MD, PhD
2015
Youth Tobacco Team, CTP
For outstanding scientific contributions regarding youth tobacco knowledge, attitudes, perceptions, and use that adds new information to the field and informs FDA's tobacco regulatory activities.
Bridget K. Ambrose, MPH, PhD
Allison C. Hoffman, MA, PhD
Benjamin J. Apelberg, MHS, PhD
Corinne G. Husten, MD, MPH
Cathy L. Backinger, MPH, PhD
Kia J. Jackson, PhD
Nicolette Borek, PhD
Sarah E. Johnson, MS, PhD
Cindy Chang, MPH, PhD
David B. Portnoy, MA, PhD, MPH
Jiping Chen, MD, PhD, MPH
Brian L. Rostron, MA, MPH, PhD
Conrad Choiniere, MS, PhD
Megan J. Schroeder, PhD
Blair N. Coleman, MPH, PhD
Candidate Greta K. Tessman, MA
Catherine G. Corey, MSPH
Cindy Tworek, MS, MPH, PhD
Baoguang Wang, MD, MPH, DrPH